Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

NCT02318329 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Gastric Cancer
Transitional Cell Carcinoma of the Bladder

Interventions

DRUG: FPA144

Sponsor

Five Prime Therapeutics, Inc.